Trading Signals: FOLD Stock Price Prediction and Forecast (Thu. May. 31, 2007 - Fri. Dec. 22, 2023)(Amicus Therapeutics Inc)
| FOLD latest price $12.4550 (2.93%) ($12.4550 - $12.4650) on Tue. Jan. 4, 2022. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.27% (three month average) | RSI | 73 | Latest Price | $12.4550(2.93%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | FOLD advances 1% a day on average for past five trading days. | Weekly Trend | FOLD advances 5.4% a week on average for past two weeks. | Market Behavior | Rotation from growth to value for large cap. Rotation from growth to value for small cap. | Correlated ETFs | Broad market will support FOLD advance at 0% a week (0% probability) IBB(60%) IWO(53%) IWC(49%) IWM(49%) XBI(48%) | Factors Impacting FOLD price | FOLD will decline at least -1.635% in a week (0% probabilities). VIXM(-29%) VXX(-13%) UUP(-12%) UNG(-8%) EDOC(-3%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.635% (StdDev 3.27%) | Hourly BBV | 1.8 () | Intraday Trend | 0% | | | |
|
5 Day Moving Average | $11.94(4.31%) | 10 Day Moving Average | $11.92(4.49%) | 20 Day Moving Average | $11.34(9.83%) | To recent high | 0% | To recent low | 27% | Market Cap | $3.216b | | | | Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and delivering medicines for people living with rare metabolic diseases. The company is committed to advancing and expanding a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. Amicus Therapeutics has a portfolio of product opportunities including the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants; a novel, clinical-stage, treatment paradigm for Pompe disease; and a rare disease gene therapy portfolio. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ. |